• Return to Headlines

Merck & Co has the Lowest Projected Earnings Growth in the Pharmaceuticals Industry (MRK, PRGO, BMY, CTLT, PBH)

By Nick Russo

Below are the three companies in the Pharmaceuticals industry with the lowest projected earnings growth. The growth of earnings per share (current fiscal year estimated vs. last year actual) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Merck & Co ranks lowest with a projected earnings growth of 4.6%. Following is Perrigo Co Plc with a projected earnings growth of 8.0%. Bristol-Myer Sqb ranks third lowest with a projected earnings growth of 8.3%.

Catalent Inc follows with a projected earnings growth of 9.0%, and Prestige Brands rounds out the bottom five with a projected earnings growth of 9.0%.

SmarTrend recommended that its subscribers protect gains by selling shares of Prestige Brands on January 31st, 2018 by issuing a Downtrend alert when the shares were trading at $42.25. Since that call, shares of Prestige Brands have fallen 25.8%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: lowest projected earnings growth Merck & Co perrigo co plc bristol-myer sqb catalent inc prestige brands

Ticker(s): MRK PRGO BMY CTLT PBH